Circularly polarized light emission and detection by chiral inorganic semiconductors

Chiral inorganic semiconductors with high dissymmetric factor are highly desirable,but it is generally difficult to induce chiral structure in inorganic semiconductors because of their structure rigidity and symmetry.In this study,we introduced chiral ZnO film as hard template to transfer chirality to CsPbBr_(3) film and PbS quantum dots(QDs)for circularly polarized light(CPL)emission and detection,respectively.The prepared CsPbBr_(3)/ZnO thin film exhibited CPL emission at 520 nm and the PbS QDs/ZnO film realized CPL detection at 780 nm,featuring high dissymmetric factor up to around 0.4.The electron transition based mechanism is responsible for chirality transfer.

Construction of MoS2 field effect transistor sensor array for the detection of bladder cancer biomarkers

Bladder cancer is one of the commonest malignant tumors of urinary system with high recurrence. However, currently developed bladder cancer urine diagnosis methods are hindered by the low detection sensitivity and accuracy. Herein, a molybdenum disulfide(MoS2) nanosheets-based field effect transistor(FET) sensor array was constructed for simultaneous detection of multiple bladder cancer biomarkers in human urine. With the excellent electronic property of MoS2 and the high specific identification capability of recognition molecules, the proposed biosensor array could simultaneously detect nuclear matrix protein 22(NMP22) and cytokeratin 8(CK8) with a wide linear range of 10-6–10-1 pg mL-1 and an ultra-low detection limit of 0.027 and 0.019 aM, respectively. Furthermore, this highly sensitive and specific MoS2 FET sensor array could be used to identify bladder cancer biomarkers from human urine samples. This designed high-performance biosensor array shows great potential in the future diagnosis of bladder cancer.

Design of high stability thin-film transistor biosensor for the diagnosis of bladder cancer

Bladder cancer is the most common malignant tumor in the urinary system,with high morbidity,mortality and recurrence after surgery.However,current bladder cancer urine diagnosis methods are limited by the low accuracy and specificity due to the low abundance of bladder cancer biomarkers in the urine with complex biological environments.Herein,we present a high stability indium gallium zinc oxide field effect transistor(IGZO-FET)biosensor for efficient identification of bladder cancer biomarkers from human urine samples.The recognition molecular functionalized IGZO-FET biosensor exhibits stable electronic and sensing performance due to the large-area fabrication of IGZO thin-film FET.Owing to the excellent electrical performance of IGZO-FET,the IGZO-FET biosensor exhibits high sensitivity and extremely low detection limit(2.7 amol/L)towards bladder cancer biomarkers.The IGZO-FET biosensor is also able to directly detect bladder tumor biomarker in human urine with high sensitivity and specificity,and could differentiate bladder cancer patients’urine samples from healthy donors effectively.These results indicate that our designed high-performance biosensor shows great potential in the application of portable digital bladder cancer diagnosis devices.

Folic acid-modified Exosome-PH20 enhances the efficiency of therapy via modulation of the tumor microenvironment and directly inhibits tumor cell metastasis

High accumulation of hyaluronan(HA)in the tumor microenvironment leads to an increase in the interstitial pressure and reduction perfusion of drugs.Furthermore,high molecular-weight(HMW)-HA suppresses M1 macrophage polarization,enhances M2 polarization,and induces immunosuppression.Hyaluronidase treatment have attempted to decrease the quantity of HA in tumors.However,hyaluronidase-driven HA degradation driven accelerates tumor cell metastasis,which is a major cause of mortality in cancer patients.Thus,we designed a novel exosome-based drug delivery system(DDS),named Exos-PH20-FA,using genetic engineering to express human hyaluronidase(PH20)and self-assembly techniques to modify the exosomes with folic acid(FA).Our results show that Exos-PH20-FA degraded HMW-HA to low-molecular-weight(LMW)-HA.Moreover,LMW-HA polarized macrophages to the M1 phenotype and reduced the number of relevant immunosuppressive immunocytes which changed the immune microenvironment from an immunosuppressive to immunosupportive phenotype.Furthermore,we demonstrated Exos-PH20-FA directly reduced hyaluronidase-induced metastasis of tumor cells.This tumor treatment also allowed an enhanced delivery of chemotherapy by tumor-targeting effect with FA modification.Our findings indicate that Exos-PH20-FA improves tumor treatment efficiency and reduces the side effects of hyaluronidase treatment,namely tumor cell metastasis.This all-in-one exosome-based HA targeting DDS maybe a promising treatment that yields more efficient and safer results.

Construction of high stability indium gallium zinc oxide transistor biosensors for reliable detection of bladder cancer-associated microRNA

Bladder cancer is the most common malignant tumours with high morbidity, mortality and recurrence.However, currently developed detection methods for bladder cancer-associated urine biomarkers are hindered by their extremely low abundance. Hence, the exploration of a highly sensitive and selective approach for the detection of trace bladder cancer-associated biomarkers in human urine is of vital importance for the diagnosis of bladder cancer. Herein, we developed a highly reliable indium gallium zinc oxide field effect transistor(IGZO FET) biosensor for the detection of bladder cancer-related biomarker micro RNA. The single-stranded DNA-functionalized IGZO FET biosensors exhibit high sensing reproducibility and stability with an ultralow detection limit of 19.8 amol/L. The device could also be used for quantitative detection of trace micro RNA in human urine samples and can effectively distinguish bladder cancer patients from healthy donors. The development of high performance IGZO FET biosensors presents new opportunities for the achievement of early-stage diagnosis of bladder cancer.